# Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

> **NCT07237256** · PHASE3 · RECRUITING · sponsor: **UNICANCER** · enrollment: 3902 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Chemotherapy followed by endocrine therapy and ribociclib treatment
- **OTHER:** De-escalation

## Key facts

- **NCT ID:** NCT07237256
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2033-11-30
- **Final completion:** 2037-12-31
- **Target enrollment:** 3902 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07237256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07237256, "Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07237256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*